A rhinopithecus swarm optimization algorithm for complex optimization problem.

This paper introduces a novel meta-heuristic algorithm named Rhinopithecus Swarm Optimization (RSO) to address optimization problems, particularly those involving high dimensions. The proposed algorithm is inspired by the social behaviors of different groups within the rhinopithecus swarm. RSO categorizes the swarm into mature, adolescent, and infancy individuals. Due to this division of labor, each category of individuals employs unique search methods, including vertical migration, concerted search, and mimicry. To evaluate the effectiveness of RSO, we conducted experiments using the CEC2017 test set and three constrained engineering problems. Each function in the test set was independently executed 36 times. Additionally, we used the Wilcoxon signed-rank test and the Friedman test to analyze the performance of RSO compared to eight well-known optimization algorithms: Dung Beetle Optimizer (DBO), Beluga Whale Optimization (BWO), Salp Swarm Algorithm (SSA), African Vultures Optimization Algorithm (AVOA), Whale Optimization Algorithm (WOA), Atomic Retrospective Learning Bare Bone Particle Swarm Optimization (ARBBPSO), Artificial Gorilla Troops Optimizer (GTO), and Harris Hawks Optimization (HHO). The results indicate that RSO exhibited outstanding performance on the CEC2017 test set for both 30 and 100 dimension. Moreover, RSO ranked first in both dimensions, surpassing the mean rank of the second-ranked algorithms by 7.69% and 42.85%, respectively. Across the three classical engineering design problems, RSO consistently achieves the best results. Overall, it can be concluded that RSO is particularly effective for solving high-dimensional optimization problems.

Mogroside IIe Ameliorates Cardiomyopathy by Suppressing Cardiomyocyte Apoptosis in a Type 2 Diabetic Model.

Mogroside IIe is primarily present in the unripe fruit of Siraitia grosvenorii (Swingle) C. Jeffrey, and it is the predominant saponin component. The purpose of this study was to investigate the effects of mogroside IIe (MGE IIe) on myocardial cell apoptosis in diabetic cardiomyopathy (DCM) rats by establishing a high-sugar and high-fat diet-induced model of type 2 diabetes (T2D) in SD rats and a homocysteine (Hcy)-induced apoptotic model in rat H9c2 cardiomyocytes. The results showed that MGE IIe decreased the levels of fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL) levels, but increased the levels of high-density lipoprotein (HDL) in the SD rat model. Furthermore, MGE IIe decreased the levels of lactate dehydrogenase 2 (LDH2), creatine phosphokinase isoenzyme (CKMB), and creatine kinase (CK), and improved heart function. Additionally, MGE IIe inhibited the secretion of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α), improved myocardial morphology, and reduced myocardial apoptosis in the SD rat model. Furthermore, MGE IIe inhibited the mRNA and protein expression of active-caspase-3, -8, -9, -12, and Bax and Cyt-C, and promoted the mRNA and protein expression of Bcl-2 in the SD rat model. Furthermore, MGE IIe suppressed homocysteine-induced apoptosis of H9c2 cells by inhibiting the activity of caspases-3, -8, -9, and -12. In conclusion, MGE IIe inhibits the apoptotic pathway, thereby relieving DCM in vivo and in vitro.